Clinical studyPrognostic value of a persistently positive technetium-99m Stannous pyrophosphate (cas 15578-26-4) myocardial scintigram after myocardial infarction

Add time:09/07/2019    Source:sciencedirect.com

Technetium-99m Stannous pyrophosphate (cas 15578-26-4) myocardial scintigrams were obtained in 138 clinically stable patients 32.7 ± 47.3 weeks (range 6 to 260) after acute myocardial infarction. Of the 138 patients, 74 (54 percent) had a persistently positive scintigram. Patients with such a scintigram were more likely to have severe angina pectoris, compensated congestive heart failure, anterior location of acute myocardial infarction, Q waves and S-T segment elevation in the electrocardiograms, cardiomegaly, left ventricular dyssynergy (dyskinesia or global dyssynergy), and an ejection fraction of less than 50 percent. During a follow-up period of 11.6 ± 6.9 months after scintigraphy, 42 percent of the patients with a persistently positive scintigram had either a cardiac death, a nonfatal myocardial infarction, unstable angina pectoris or decompensated congestive heart failure compared with 13 percent of the patients with a negative scintigram (P < 0.001). Of the 14 patients with cardiac death, 13 (93 percent) had a persistently positive scintigram. A persistently positive scintigram not only was the best single predictor of cardiac death and combined end points, but also added significantly to the predictive ability of the other clinical variables, including age, location of acute myocardial infarct, clinical status, electrocardiographic findings, and chest X-ray findings. It is concluded that technetium-99m stannous pyrophosphate myocardial scintigraphy has prognostic value in patients after acute myocardial infarction.

We also recommend Trading Suppliers and Manufacturers of Stannous pyrophosphate (cas 15578-26-4). Pls Click Website Link as below: cas 15578-26-4 suppliers

Prev:Experimental StudyMechanisms contributing to myocardial accumulation of technetium-99m Stannous pyrophosphate (cas 15578-26-4) after coronary arterial occlusion*
Next:Chapter 3 - Drug delivery and cycloaddition reactions)